Recombinant Human RBP1, N-His

Description of Recombinant Human RBP1, N-His

Introduction

Recombinant Human RBP1, N-His is a protein that plays a crucial role in the regulation of gene transcription and is a potential drug target for various diseases. This article will provide a detailed description of the structure, activity, and potential applications of this protein.

Structure of Recombinant Human RBP1, N-His

Recombinant Human RBP1, N-His is a 120 kDa protein that consists of 1089 amino acids. It is a member of the retinoblastoma-binding protein (RBP) family and is encoded by the RBP1 gene. The protein contains several functional domains, including an N-terminal domain, a C-terminal domain, and a central domain. The N-terminal domain is responsible for binding to retinoblastoma protein (RB), while the C-terminal domain is involved in transcriptional activation. The central domain contains a zinc finger motif and is essential for DNA binding and protein-protein interactions.

Activity of this protein

Recombinant Human RBP1, N-His plays a crucial role in regulating gene transcription. It functions as a transcriptional co-regulator, interacting with various transcription factors to either activate or repress gene expression. The protein binds to RB, a tumor suppressor protein, and inhibits its activity, leading to the activation of genes involved in cell proliferation and differentiation. Additionally, Recombinant Human RBP1, N-His can also interact with other transcription factors, such as E2F and p53, to regulate their activity and modulate gene expression.

Applications of Recombinant Human RBP1, N-His

Recombinant Human RBP1, N-His has been identified as a potential drug target for various diseases, including cancer and neurodegenerative disorders. As a transcriptional co-regulator, this protein plays a critical role in cell proliferation and differentiation, making it an attractive target for cancer therapy. Inhibition of Recombinant Human RBP1, N-His activity has been shown to suppress tumor growth and induce cell death in various cancer cell lines.

Moreover, Recombinant Human RBP1, N-His has also been implicated in neurodegenerative disorders, such as Alzheimer’s disease. Studies have shown that this protein is involved in the regulation of amyloid beta precursor protein (APP) processing, a key event in the development of Alzheimer’s disease. Inhibition of Recombinant Human RBP1, N-His activity has been shown to reduce the production of beta-amyloid, a toxic protein that forms plaques in the brain, leading to cognitive decline.

Conclusion

In conclusion, Recombinant Human RBP1, N-His is a 120 kDa protein that plays a crucial role in regulating gene transcription. It contains functional domains that are involved in DNA binding, protein-protein interactions, and transcriptional activation. This protein has been identified as a potential drug target for various diseases, including cancer and neurodegenerative disorders. Further research on the structure and activity of Recombinant Human RBP1, N-His may lead to the development of novel therapies for these diseases.